-
In postmenopausal women, constipation is associated with having major risk factors for cardiovascular disease and increased cardiovascular risk.
-
This basic science paper explores the role of the tumor microenvironment in the development of tumor resistance to chemotherapy. Two distinct fatty acid molecules, endogenously produced by cancer cells in response to platinum-based chemotherapy drugs, were found to confer significant tumor chemoresistance. Remarkably, these two fatty acids also were shown to be present in several commercial fish oil products, and, of potential import to clinicians, the oral administration of small amounts of these fish oils induced tumor resistance to cisplatin in a mouse tumor model.
-
Sickle cell disease celebrated its 100th anniversary last year, prompting consideration of what has transpired for those with the disease since its description by Dr. James Herrick in 1910.
-
The decode data (diabetes epidemiology Collaborative Analysis of Diagnostic Criteria in Europe) indicated that all-cause mortality, as well as cardiovascular (CV) events, were better predicted by postprandial glucose (PPG) than fasting blood glucose (FPG).
-
The lead II rhythm strip shown above was obtained from a woman with new-onset palpitations. How would you interpret this tracing? How certain are you of your answer? Clinically what would you do?
-
The presence of any observed hostility at baseline was associated with a two-fold increased risk of incident ischemic heart disease over a 10-year period of observation.
-
In a large community-based cohort of older women, those who self-reported use of multivitamins, vitamin B6, folate, iron, magnesium, zinc, and copper were more likely to die than those who do not. Calcium use, however, was associated with reduced risk.
-
In a large randomized trial of healthy men, dietary supplementation with vitamin E (400 IU/day) significantly increased the risk of prostate cancer.
-
The FDA has approved the first fixed-dose combination product for the treatment of type 2 diabetes and hypercholesterolemia. This tablet combines a dipeptidyl peptidase-4 inhibitor (sitagliptin) and a HMG-CoA reductase inhibitor (simvastatin).
-
The oral administration of 500,000 IU cholecalciferol in fall or winter resulted in a slightly higher risk of falls and fractures vs placebo in 2,256 community-dwelling women aged 70 and above.
